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Stem cell therapy for Parkinson’s disease requires effective production of dopaminergic neurons. In this
issue of Cell Stem Cell, Sacchetti et al. (2009) report an unexpected role of liver X receptors and their ligand,
oxysterols, in regulating dopaminergic neurogenesis.Midbrain dopaminergic neurons are impor-
tant for coordinating voluntary move-
ments and for regulating diverse cognitive
functions. Degenerative loss of dopami-
nergic neurons is a hallmark of Parkinson’s
disease (PD). Pioneering works indicated
initial promise of transplanting fetal neural
tissues to replace lost dopaminergic
neurons and ameliorate certain patholog-
ical symptoms of PD patients (Lindvall
et al., 1990). Such attempts fueled hopes
to use better-defined stem cell-derived
dopaminergic neurons in treating PD and
to circumvent logistic and ethical issues
associated with fetal human tissue trans-
plantation. Dopaminergic neurons have
since been successfully generated from
embryonic stem cells (ESCs) and tested in
preclinical animal models (Gale and Li,
2008; Kim and de Vellis, 2009; McKay,
2004). The beneficial outcome, however,
is limited and variable, in part because of
inefficient ex vivo differentiation of dopami-
nergic neurons from ESCs. Therefore, a
better understanding of extrinsic and
intrinsic mechanisms underlying dopami-
nergicneurogenesisduring midbrain devel-
opment should illuminate how to further
enhance directed dopaminergic differenti-
ation from ESCs. In this issue of Cell Stem
Cell, Sacchetti et al. (2009) report a critical
role of liver X receptors (LXRs) in ventral
midbrain neurogenesis. Moreover, oxyster-
ols,naturalagonistsofLXRs,enhancedopa-
minergic neurogenesis from human ESCs.
The generation of specific neuronal
subtypes and glia in the developing brain
is subjected to precise temporal and
spatial control involving coordinated
interaction between extrinsic inductive
signals and intrinsic genetic programs.Previous studies have revealed Shh and
Fgf8 as two key inductive signals for estab-
lishing the ventral midbrain (VM) identity
(Gale and Li, 2008). VM neural progenitors
upregulate a battery of genes, including
Wnt1, Lmx1a, Ngn2, Pitx3I, and Nurr1,
and undergo differentiation to become
postmitotic dopaminergic neurons ex-
pressing tyrosine hydroxylase (TH). The
maturation and survival of dopaminergic
neurons are then regulated by neurotro-
phins GDNF and BDNF. LXRs are nuclear
receptors, best known as intracellular
sensors for various sterols in multiple adult
organs, and they regulate gene transcrip-
tion in response to oxysterols, oxidized
derivatives of cholesterol (Kalaany and
Mangelsdorf, 2006). In the nervous
system, LXRs were recently implicated in
preventing degeneration of dopaminergic
neurons in adult mice through maintaining
proper lipid homeostasis (Kim et al., 2008).
By characterizing dopaminergic neuro-
genesis in LXR null mice and in culture,
Sacchetti et al. (2009) presented a series
of compelling findings that support
a surprising developmental role for LXRs
during midbrain dopaminergic neuron
generation, via mechanisms other than
lipid homeostatic regulation (Figure 1).
To probe potential roles of LXRs in
midbrain development, the authors found
that the spatiotemporal expression pattern
of LXRs (LXRaand LXRb) in the VM domain
is highly correlated with dopaminergic
neuron generation. Furthermore, LXRab
null mice exhibit reduced expression of
a specific subset of genes important for
dompaminergic neurogenesis, including
Limx1b, Wnt1, and Pitx3, and reduced
numbers of TH+ or Nurr+ dopaminergicCell Stem Celneurons at E11.5. In parallel culture exper-
iments with primary mouse VM progeni-
tors, both overexpression of LXRb and
application of exogenous LXR agonist oxy-
sterols enhance dopaminergic neurogene-
sis, and these two manipulations exhibit
additive effects. Importantly, the neuro-
genic enhancing effect of oxysterols is
abolished in LXR-deficient progenitors,
indicating specific action of oxysterols on
LXRs to yield this outcome. Collectively,
these experiments established that activa-
tion of LXRs is both required and sufficient
to promote dopaminergic neurogenesis.
Surprisingly, LXRs do not seem to directly
bind to and regulate Wnt1, Lmx1b, or
Ngn2, all of which are genes that exhibit
altered expression in LXR null mice. To
further explore the underlying mechanism
responsible for the observed dopami-
nergic neurogenesis, the authors ruled
out potential contributions stemming from
cell death or lipid homeostatic dysregula-
tion. Instead, combined Ki67- and BrdU-
labeling analysis suggested that LXR
deficiency causes delayed or impaired
cell-cycle progression of proliferating
progenitors at the G2/M phase, leading to
progenitor accumulation and impairment
of differentiation required for dopaminergic
neurogenesis. Accordingly, the authors
observed bidirectional expression level
changes of cyclin-dependent kinase inhib-
itor p27Kip upon LXR activation or in LXR-
deficient cultures, although the causal
role of p27Kip remains to be determined.
Importantly, the authors proceeded to
apply the new insights gained in their
mouse studies to promote dopaminergic
differentiation of human ESCs. Conven-
tional protocols use PA6 stromal feedersl 5, October 2, 2009 ª2009 Elsevier Inc. 343
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GDNF, and BDNF, and yet
the efficiency of these condi-
tions for dopaminergic neuron
generation remains low (Gale
and Li, 2008; Kim and de
Vellis, 2009). Treatment with
oxysterols during neuronal
differentiation of human ESCs
markedly increases the pro-
duction of TH+ neurons, along
with concurrent reduction in
the numbers of astrocytes,
neural progenitors, and prolif-
erative cells (Figure 1). These
TH+ neurons appear to
have acquired many hallmarks
of dopaminergic neurons,
including depolarization-in-
duced release of dopamine,
and seem to be metabolically
normal with respect to cellular
lipid and cholesterol homeo-
stasis. One challenge that
must be overcome prior to
wide application of stem
cell-based cell replacement
therapy is the ability to
generate desired cell types in
large quantities that are also
of high quality and sufficient
purity so as to minimize con-
tamination of undesired cells,
especially proliferating progenitors that
may cause tumorigenesis after transplan-
tation. Oxysterols enhance dopaminergic
neuronal differentiation, promote cell-cycle
exit, and decrease gliogenesis of stem cells
and thus kill multiple birds with one stone.
The majority of identified nuclear recep-
tors are known to be expressed in the
embryonic and adult brain, and yet few
have been investigated as to their potential
roles in regulating neurogenesis and devel-
opment, with the exception of retinoic acid
receptor. The identification of novel func-
tions of LXRs in neurogenesis, distinct
from their classic roles in lipid homeostasis,
opens doors for studying other nuclear
receptors in neural development. This
study also illustrates a prime example of
how discoveries in basic developmental
biology can be highly instructive for
improving practical schemes of thera-
peutic stem cell applications. Several
important issues, however, remain to be
addressed by future studies. First, the
mechanism responsible for the impact of
oxysterol/LXRs on cell-cycle dynamics of
dopaminergic neural progenitors remains
unclear. Activation of LXRs has been
shown to suppress key cell-cycle genes
in other cell types (Vedin et al., 2009). Iden-
tifying direct targets of LXRs through Chip-
on-chip or Chip-seq technologies would
yield insights into this issue. Given that
Shh and retinoic acid signaling compo-
nents exhibit altered expression in acute
response to oxysterols or in LXR null mice
(Dwyer et al., 2007; Volle et al., 2007), these
pathways represent attractive candidates
as potential LXR targets, and as
converging points that may couple oxy-
sterol signaling to known genetic programs
for dopaminergic neuron specification.
Second, LXR-mediated effects appear to
be highly specific for the midbrain region,
for the dopaminergic neuron subtype, and
for a subset of dopaminergic specification
genes. How is such specificity achieved?
How is oxysterol/LXR signaling initiated
and regulated in different biological
contexts? From the perspective of disease
and stem cell-based therapeutic interven-
tions, screening for more potent LXR
agonists and inducers of LXR
expression is warranted, given
the observed additive effects
of oxysterols and overexpres-
sion of LXRb on dopaminergic
neurogenesis. Additional work
is also needed to understand
whether defective oxysterol/
LXR signaling might be
involved in predisposing PD
patients for the onset of symp-
toms. Furthermore, it will be
interesting to assay how oxy-
sterol-like molecules might be
used to augment dopami-
nergic neurogenesis from
other stem cell populations,
such as adult neural stem
cells and PD patient-specific
induced pluripotent stemcells.
Success in these endeavors
may offer meaningful ad-
vances for both preclinical
and translational applications,
as well as drug testing and
in vitro disease modeling.
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Figure 1. A Schematic Illustration of The role of Oxysterols in
Promoting Dopaminergic Neurogenesis
Dopaminergic neural progenitors undergo active cell-cycle progression in the
ventral midbrain domain from the mouse embryonic stage E9 to E12 and then
dopaminergic neuron fate determination and maturation from the stage E11 to
E15 (A). Acting in the nuclei of the early progenitors in a presumably cell-auton-
omous manner, oxysterols (22-oxycholesterol depicted) activate LXRs and
regulate target gene transcription to induce cell-cycle exit and dopamine
neuron differentiation. Such effects of oxysterols are conserved during dopa-
minergic neurogenesis from human embryonic stem cells (B). Shh and Fgf8
induce neural progenitor cell competency for midbrain neuron specification.
By inducing cell-cycle exit specifically toward neuronal fate, oxysterols then
act in coordination with other factors and genetic programs to promote dopa-
minergic neuron differentiation from progenitor cells.344 Cell Stem Cell 5, October 2, 2009 ª2009 Elsevier Inc.
